BRIEF—Vemlidy to be reimbursed in Taiwan

Gilead Sciences has won a positive reimbursement decision in Taiwan for its once-daily hepatitis B medicine Vemlidy (tenofovir alafenamide). The approval covers adults with compensated liver disease.

There are around 2.2 million hepatitis B infections in Taiwan, and around 90% of the patient population is untreated.

Vemlidy was approved in the USA and Japan in 2016, and in Taiwan and Europe in 2017.